HBM Healthcare Investments (Cayman) Ltd.

Average Profitability
<0.0001%
Insider Buys Quantity
5
Insider Buys Sum
$31.05M
Insider Sells Quantity
7
Insider Sells Sum
$68.46M

Insider Activity of HBM Healthcare Investments (Cayman) Ltd.

The largest purchase of all time was on 2013-06-25 and amounted to 666676 shares of PTC Therapeutics, Inc. for $10M.

The largest sale of all time was on 2013-03-11 and amounted to 1000000 shares of Pacira BioSciences, Inc. for $27.86M.

Biography of HBM Healthcare Investments (Cayman) Ltd.

No biography is available at this moment.

2023-02-14PurchaseMineralys Therapeutics, Inc.
MLYS
10 percent owner
312,500
0.7867%
$16.00$5M-31.82%
2021-11-09PurchaseIO Biotech, Inc.
IOBT
10 percent owner
325,000
7.8787%
$14.00$4.55M-62.27%
2013-12-17SalePTC Therapeutics, Inc.
PTCT
10 percent owner
66,667
0.2712%
$19.08$1.27M+45.01%
2013-06-25PurchasePTC Therapeutics, Inc.
PTCT
10 percent owner
666,676
2.3952%
$15.00$10M+8.52%
2013-03-25SalePacira BioSciences, Inc.
PCRX
10 percent owner
331,082
1.0099%
$28.28$9.36M+49.01%
2013-03-22SalePacira BioSciences, Inc.
PCRX
10 percent owner
227,856
0.6947%
$27.52$6.27M+50.18%
2013-03-21SalePacira BioSciences, Inc.
PCRX
10 percent owner
22,862
0.0699%
$27.50$628,705+49.85%
2013-03-19SalePacira BioSciences, Inc.
PCRX
10 percent owner
18,200
0.0573%
$27.86$507,001+50.91%
2013-03-18SalePacira BioSciences, Inc.
PCRX
10 percent owner
800,000
2.4383%
$28.19$22.55M+44.02%
2013-03-11SalePacira BioSciences, Inc.
PCRX
10 percent owner
1M
2.909%
$27.86$27.86M+28.59%
2011-11-21PurchasePacira BioSciences, Inc.
PCRX
10 percent owner
615,384
3.3199%
$6.50$4M+54.02%
2011-02-08PurchasePacira BioSciences, Inc.
PCRX
10 percent owner
1.07M
11.1451%
$7.00$7.5M+33.11%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.